日期 | 股东名称 | 披露原因 | 买入/卖出涉及 的股份数目 |
每股平均价 | 持有权益的 股份数目 |
占已发行 股本(%) |
10/07/2023 | UBS Group AG | 1104(L) | +136,534,866(L) | 542,694,590(L) 367,512,793(S) | 14.43 9.77 | |
10/07/2023 | UBS Group AG | 1104(L) | +288,792,900(L) | 694,952,624(L) 367,512,793(S) | 18.47 9.77 | |
03/07/2023 | UBS Group AG | 1201(L) | -8,253,000(L) | HKD3.318(L) | 409,373,380(L) 372,451,793(S) | 10.88 9.90 |
30/06/2023 | 刘殿波 | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
30/06/2023 | UBS Group AG | 1201(L) | -68,750,000(L) | HKD3.535(L) | 414,017,118(L) 368,053,174(S) | 11.01 9.78 |
30/06/2023 | Shorea LBG | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
30/06/2023 | Ginkgo (PTC) Limited | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
30/06/2023 | Nelumbo Investments Limited | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
30/06/2023 | Luye Life Sciences Group Ltd | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
30/06/2023 | LuYe Pharmaceutical International Co., Ltd. | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
30/06/2023 | Luye Pharma Holdings Ltd. | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
30/06/2023 | LuYe Pharmaceutical Investment Co., Ltd. | 1313(L) | 218,500,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
28/06/2023 | UBS Group AG | 1013(L) 1402(S) | +300,554,500(L) +218,500,000(S) | 477,797,810(L) 365,647,890(S) | 12.70 9.72 | |
28/06/2023 | 易方达基金管理有限公司 | 1001(L) | +6,631,000(L) | HKD3.519(L) | 192,746,000(L) | 5.12 |
03/05/2023 | Nelumbo Investments Limited | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Nelumbo Investments Limited | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | LuYe Pharmaceutical International Co., Ltd. | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Luye Life Sciences Group Ltd | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | LuYe Pharmaceutical International Co., Ltd. | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Ginkgo (PTC) Limited | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Ginkgo (PTC) Limited | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Luye Pharma Holdings Ltd. | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Luye Pharma Holdings Ltd. | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Shorea LBG | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | 刘殿波 | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | 刘殿波 | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Luye Life Sciences Group Ltd | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | LuYe Pharmaceutical Investment Co., Ltd. | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | LuYe Pharmaceutical Investment Co., Ltd. | 1313(L) | 128,160,000(L) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
03/05/2023 | Shorea LBG | 14015(S) | +128,160,000(S) | 1,257,196,703(L) 200,861,950(S) | 33.42 5.34 | |
22/02/2023 | LuYe Pharmaceutical Investment Co., Ltd. | 1213(L) | 1,257,196,703(L) 72,701,950(S) | 33.42 1.93 | ||
22/02/2023 | 刘殿波 | 1213(L) | 1,257,196,703(L) 72,701,950(S) | 33.42 1.93 | ||
22/02/2023 | Shorea LBG | 1213(L) | 1,257,196,703(L) 72,701,950(S) | 33.42 1.93 | ||
22/02/2023 | Hillhouse Fund V, L.P. | 1213(L) | 552,324,108(L) | 14.68 | ||
22/02/2023 | Nelumbo Investments Limited | 1213(L) | 1,257,196,703(L) 72,701,950(S) | 33.42 1.93 | ||
22/02/2023 | Luye Life Sciences Group Ltd | 1213(L) | 1,257,196,703(L) 72,701,950(S) | 33.42 1.93 | ||
22/02/2023 | LuYe Pharmaceutical International Co., Ltd. | 1213(L) | 1,257,196,703(L) 72,701,950(S) | 33.42 1.93 | ||
22/02/2023 | Luye Pharma Holdings Ltd. | 1213(L) | 1,257,196,703(L) 72,701,950(S) | 33.42 1.93 | ||
22/02/2023 | Ginkgo (PTC) Limited | 1213(L) | 1,257,196,703(L) 72,701,950(S) | 33.42 1.93 | ||
22/02/2023 | Hillhouse NEV Holdings Limited | 1213(L) | 552,324,108(L) | 14.68 | ||
1 2 3 4 5 |
备注: | (L) - 长仓:包括 (1) 持有股份;(2) 透过持有丶沽出或发行金融合约,有权或有责任购买相关股份。 |
(S) - 短仓:包括 (1) 借入股份;(2) 透过持有丶沽出或发行金融合约,有权或有责任沽出相关股份。 | |
(P) - 可供借出的股份 | |
即时报价更新时间为 30/09/2024 17:59 | |
港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |